Role of tumor-associated macrophages (TAM) in advanced gastric carcinoma: The impact on FasL-mediated counterattack

Anticancer Research

Volumn 25, Issue 1 B, 2005, Pages 463-470

  Ohno, Satoshi ^a,b   Inagawa, Hiroyuki ^c,d   Dhar, Dipok Kumar ^b   Fujii, Toshiyuki ^b   Ueda, Shuhei ^b   Tachibana, Mitsuo ^b   Ohno, Yumiko ^a   Suzuki, Nobutaka ^a   Inoue, Masaki ^a   Soma, Gen Ichiro ^c,d   Nagasue, Naofumi ^b  

^a KANAZAWA UNIVERSITY   (Japan)

^b SHIMANE UNIVERSITY   (Japan)

^c TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^d TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Cytotoxic T lymphocyte (CTL); Fas ligand (FasL); Gastric cancer; Immunomodulation; Prognosis; Tumor associated macrophages (TAM)

Indexed keywords

CD68 ANTIGEN; CD8 ANTIGEN; FAS LIGAND;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER IMMUNOLOGY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; NICK END LABELING; PRIORITY JOURNAL; PROGNOSIS; STOMACH CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD34; ANTIGENS, CD8; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INFLAMMATION; MACROPHAGES; MALE; MEMBRANE GLYCOPROTEINS; MICROCIRCULATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECURRENCE; STOMACH NEOPLASMS; TIME FACTORS;

EID: 20144388010     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, Goto M and the Gastric Cancer Surgical Study Group: Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet 354: 273-277, 1999.
2. Noguchi N, Yoshikawa T, Tsuburaya A, Motohashi H, Karpeh MS and Brennan M F: Is gastric carcinoma different between Japan and the United State? Cancer 89: 2237-2246, 2000.
3. Ohno S, Tachibana M, Fujii T, Ueda S, Kubota H and Nagasue N: Role of stromal collagen in immunomodulation and prognosis of advanced gastric carcinoma. Int J Cancer 97: 770-774, 2002.
4. Gregory CD: CD14-dependent clearance of apoptotic cells: relevance to the immune system. Curr Opin Immunol 12: 27-34, 2000.
5. Mantovani A: Biology of disease. Tumor-associated macrophage in neoplastic progression: A paradigm for the in vivo function of chemokines. Lab Invest 71: 5-16, 1994.
6. Naama HA, Mack VE, Smyth GP, Stapleton PP and Daly JM: Macrophage effector mechanisms in melanoma in an experimental study. Arch Surg 136: 804-809, 2001.
7. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK and Shanahan F: The Fas counterattack: cancer as a site of immune privilege. Immunol Today 20: 46-52, 1999.
8. O'Connell J, Houston A, Bennett MW, O'Sullivan GC and Shanahan F: Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 7: 271-274, 2001.
9. Koomägi R and Volm M: Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 84: 239-243, 1999.
10. Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, Ko S, Yagita H, Yamada T, Okumura K and Nakano H: The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology 30: 413-421, 1999.
11. Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H, Masunaga R and Nagasue N: Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res 5: 2464-2469, 1999.
12. Munakata S, Enomoto T, Tsujimoto M, Otsuki Y, Miwa H, Kanno H and Aozasa K: Expression of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer 82: 1446-1452, 2000.
13. Reimer T, Herrnring C, Koczan D, Richter D, Gerber B, Kabelitz D, Friese K and Thiesen HJ: FasL: Fas ratio - a prognostic factor in breast carcinomas. Cancer Res 60: 822-828, 2000.
14. Ohno S, Tachibana M, Shibakita M, Dhar DK, Yoshimura H, Kinugasa S, Kubota H, Masunaga R and Nagasue N: Prognostic significance of Fas and Fas ligand system associated apoptosis in gastric cancer. Ann Surg Oncol 7: 750-757, 2000.
15. Seino K, Kayagaki N, Okumura K and Yagita H: Antitumor effect of locally produced CD95 ligand. Nat Med 3: 165-170, 1997.
16. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H and Ohtani H: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58: 3491-3494, 1998.
17. Bennett MW, O'Connell J, O'Sullivan GC, Roche D, Brady C, Kelly J, Collins JK and Shanahan F: Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut 44: 156-162, 1999.
18. Svennevig JL and Svaar H: Content and distribution of macrophages and lymphocytes in solid malignant human tumours. Int J Cancer 24: 754-758, 1979.
19. Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, Nishioka Y, Sone S and Kuwano M: Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFα and IL-1α. Int J Cancer 85: 182-188, 2000.
20. Liss C, Fekete MJ, Hasina R, Lam CD and Lingen MW: Paracrine angiogenic loop between head-and-neck squamous-cell carcinoma and macrophage. Int J Cancer 93: 781-785, 2001.
21. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J and Harris L: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56: 4625-4629, 1996.
22. Takanami I, Takeuchi K and Kodaira S: Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology 57: 138-142, 1999.
23. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY and Henson PM: Macrophages that have ingested apoptotic cells in vitro inhibits proinflammatory cytokine production through autocrine/paracrine mechanism involving TGF-β, PGE2, and PAF. J Clin Invest 101: 890-898, 1998.
24. McDonald PP, Fadok VA, Bratton D and Henson PM: Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF-β in macrophages that have ingested apoptotic cells. J Immunol 163: 6164-6172, 1999.
25. Tada T, Ohzeki S, Utsumi K, Takiuchi H, Muramatsu M, Li X, Shimizu J, Fujiwara H and Hamaoka T: Transforming growth factor-β-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in tumor-bearing state. J Immunol 146: 1077-1082, 1991.
26. Brown SB and Savill J: Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. J Immunol 162: 480-485, 1999.
27. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A and Thompson TC: Reduced infiltration of tumor-associated macrophage in human prostate cancer: association with cancer progression. Cancer Res 60: 5857-5861, 2000.